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To stop the spread of any epidemic, it
is essential to know where and among
whom the infection is spreading and the
impact of potential interventions. Thus,
accurate information on the incidence
rate of HIV—the rate of new infections
in a population—could substantially
strengthen and increase the efficiency of
the response to the global HIV epidemic.
A method to quickly and reliably estimate
the incidence of HIV would have valu-
able applications in surveillance, pro-
gramme planning, impact evaluation,
and prevention trial planning, and could
potentially provide an end point in
community- or individual-based interven-
tion trials (Box 1). Longitudinal cohorts
(observing how many uninfected individ-
ual become infected in a set period of
follow-up), mathematical models, and
H I Vp r e v a l e n c e( t h ep r o p o r t i o no fi n d i -
viduals living with infection) measures,
which have been used to estimate or
approximate incidence in the past, have
significant limitations for these applica-
tions [1,2]. However, a laboratory assay
(or algorithm of multiple assays) that can
measure a well-characterised biomarker
for the recentness of infection could be
used in a single cross-sectional survey to
measure HIV incidence. A ‘‘first gener-
ation’’ of assays of this type have been
available for more than a decade [3–5]
(recently reviewed by Murphy and Parry
[6], Mastro et al. [7], and a WHO
technical working group in Busch et al.
[8]). However, because the estimates of
incidence produced by them conflicted
with other estimates and epidemiological
information [9–14], their accuracy has
been questioned.
Our goal is to ensure that in the
future, when an estimate of HIV inci-
dence in any population is needed, a
s t a n d a r d ,a c c u r a t e ,i n e x p e n s i v e ,a n d
easy-to-use kit can be purchased com-
mercially just as easily as HIV tests can
be acquired to estimate HIV prevalence.
This would mean that HIV incidence
estimation could become routine, per-
mitting robust, up-to-date empirical in-
formation on the trajectory and focus of
t h ee p i d e m i ca n do nt h ei m p a c to fs c a l e d
interventions, and, in combination with
other epidemiological and programme
implementation information [15,16], this
would have the potential to directly
influence the programmatic decisions of
major implementers, funders, and do-
nors. In September 2010, representatives
from major stakeholder organizations
met to review the issues and establish a
strategy for achieving this goal. Major
stakeholders with diverse perspectives
were identified as key participants—
these included the US President’s Emer-
gency Plan for AIDS Relief and the
Global Fund (that need to measure
impact of programmes), the Joint United
Nations Programme on HIV/AIDS
(UNAIDS) (tasked with tracking the
course of the epidemics), the US Centers
for Disease Control and Prevention
(CDC) and World Health Organization
(WHO) (that will produce normative
guidance of the use of assays), the US
National Institutes of Health (NIH)
(where research on prevention interven-
tion evaluation is reliant on incidence
measurement, and which can support
research into new technologies), and
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Summary Points
N Investments in HIV prevention activities aiming to reduce incidence could be
targeted more effectively and efficiently to successful programmes if a quick,
easy, valid, and precise method of estimating incidence in populations were
available.
N Laboratory methods for identifying recent infections have shown promise for
this application, although their accuracy has been questioned, and progress
and investment in this field has been challenged by technical and market-
related issues.
N A number of activities are now underway to address these factors and several
promising new technologies are anticipated in the next few years.
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which have not entered the market for
incidence assays). In this article, we
summarise their analysis and the strategy
that was agreed upon (a fuller briefing
document is provided in Text S1).
Current Status of Laboratory-
Based Assays
T h ep r i n c i p l eo fat e s tf o rr e c e n ti n f e c t i o n
is to measure a biological target (‘‘biomark-
er’’) that is related to an early phase of HIV
infection (e.g., antibody concentration, pro-
portion, avidity, etc.). However, many such
biomarkers are associated with a very large
between-individual variation and this makes
it difficult to characterise the fundamental
test characteristics (Box 2). This variation
can mean that a proportion of individuals
with long-standing infection test as ‘‘recent-
ly’’ infected. The proportion of chronically
infected individuals that are misclassified as
recent—termed the false recent rate
(FRR)—has been found to vary widely
between populations; from 0.8% in south
Vietnam [17] to 16% in Uganda (before
additional screening using behavioural, im-
munologic, or virologic information)
[11,12,14,18]. This can be due to differences
in HIV subtype, epidemic phases, different
levels of total IgG in different populations,
and the extent of antiretroviral treatment
use [10,19,20]. Nevertheless, if the local and
current FRR is known accurately, it can be
factored into the resultsofthe assay to obtain
an unbiased incidence estimate [13,21–23].
However, because the measurement of the
FRR is itself a substantial undertaking (since
it requires finding a large and representative
sample of individuals with HIV known not to
have been infected recently), this has not
often been done. In a review of 39 studies
that measured HIV incidence using BED
a s s a y s ,m o s td i dn o ta c c o u n tf o ra n y
misclassification [24], and among those
studies that did assume a non-zero FRR,
the values used were not measured in the
local populations but instead were taken
from previous studies in different popula-
tions [24]. This leads to substantial errors in
the absolute level of incidence estimated and
the pattern with respect totimeand age [11–
14,19,24–27].
Another issue is the large sample sizes
required for precise incidence estimates
using incidence assays. Sample sizes to
record incidence are inevitably larger than
those required to gain the same precision in
estimates of prevalence because incident
infections are approximately 10-fold less
common than prevalent infections. But,
with current incidence assays, the need for
l a r g es a m p l es i z e si sc o m p o u n d e db yb o t h
the necessity to account for the misclassifi-
cation rate and the uncertainty in the
characteristics of the assay itself. For in-
stance, to reach an 80% chance of recording
a statistically significant change if incidence
was really reduced by half in South Africa
would require two surveys each of 6,000
adults if FRR=0%, but 15,000 adults per
survey if FRR=5% [23]. In other settings
with lower baseline incidence, or with more
modest reductions in incidence, sample sizes
would have to be even greater.
Encouragingly, a new generation of
incidence assays that are based on differ-
ent biomarkers is now in development
[28–31]. In early tests, the FRR for one
avidity assay [32] was as low as 1% [33].
There are also promising preliminary data
that algorithms (combinations of several
assays) can generate very low FRR values
(e.g., BED and a particular Bio-Rad
avidity assay in specimens from the US
has FRR=0.8% [33]). This performance
level, if reproduced in other populations
(and it is not certain that they will), could
be sufficient for reliable incidence esti-
mates across populations in surveys of
feasible sample sizes.
Challenges That Must Be
Addressed
To plan the next steps, we have tried to
identify the factors that have challenged
progress in recent years. These include the
following:
1. There has been a need for guidance and
support for developers of incidence
assays.Nonormativeagencyorscientific
body has developed performance stan-
dards that incidence assays must meet
and, because incidence assays are for
‘‘population use’’ rather than individual
diagnosis, traditional regulatory regimes
used by the US Food and Drug
Administration (and other regulatory
agencies) to evaluate and approve diag-
nostic assays have not been automati-
cally required. In the absence of guid-
ance from a scientific body or normative
agency, many assay developers have
endeavoured to evaluate their candidate
assays with any of the very few and not
fully representative seroconversion pan-
els (collections of samples taken fre-
quently from newly infected individuals)
that were readily accessible. The incom-
pleteness of these evaluations makes it
hard to identify the best assays, antici-
pate their performance at estimating
incidence in real populations, or com-
pare different assays. Development of
assays by companies has been impeded
because they typically only have access
to the small subset of all possible
specimens that have been collected and
are available commercially.
Box 1. Who Needs a Reliable HIV Incidence Assay?
Area: Impact evaluation
Function: To determine the impact of large-scale interventions on the rate of
new infections.
Users: Implementers, donors/funders, researchers, advocates.
Area: Surveillance
Function: To monitor transmission patterns, identify at-risk groups, and detect
emerging trends in epidemic.
Users: Ministries of health, donors/funders, advocates.
Area: Programme and resource planning
Function: To optimally target interventions and to plan for future service
requirements (e.g., treatment slots).
Users: Programme planners, ministries of health, advocates.
Area: Trials
Function: To estimate pre-trial incidence to inform trial planning (required
sample size, trial length, etc.), and as an end point in community-based
effectiveness trials.
Users: Clinical trial/research, organizations, funders/donors, researchers.
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guidance for the users of incidence
assays. Many assays are in use in
surveillance systems in Europe, but
there has been no guide as to the
relative strengths of each approach [6],
and for the most widely used assay (the
BED), the CDC and UNAIDS had
adopted different positions on whether
o rn o ti tc o u l db eu s e dr o u t i n e l y
[34,35]. The absence of a clear con-
sensus from major public health agen-
cies involved in HIV prevention has led
users to apply assays inconsistently.
3. There has been a lack of market
incentive for manufacturers to invest
in developing incidence assays. It has
been estimated that the global demand
for HIV incidence assays could be as
high as several million over 5 years, but
it could be as low as just a few hundred
thousand [36]. This relatively small
and uncertain market size is a signifi-
cant obstacle to investment. Another
deterrent has been the apparent lack of
consensus among public health agen-
cies about assay performance require-
ments and under what circumstances
an assay would be recommended.
Next Steps in the Critical Path
To tackle those challenges and move
towards the goal of having a thoroughly
validated incidence assay, we have charted
the activities, milestones, and decisions
that will be required in the coming years
(Figure 1). This analysis suggests that the
first validated assays (or algorithms) could
be available for use by the end of 2013.
In the critical path, attention should first
be devoted to understanding the target
product profile. This is a list of technical
specifications for the assay that meets the
performance requirements of intended users
(see Text S1). We propose that an assay with
an FRR that can be measured accurately for
the target population and is confidently not
more than 2% and a mean duration of
between 4 and 12 months, is a reasonable
acceptable target. Other key properties include
storage conditions, shelflife, and sample type.
Secondly, a repository of specimens will
be established to aggregate material from a
wide range of different populations (includ-
ing seroconverter cohorts, repeat blood
donors, and samples of individuals with
longstanding infection), viral clades, sample
types (including plasma, serum, and dried
blood spot), and epidemic setting. This
resource would be essential for a systematic
evaluation and calibration of existing inci-
dence assays and to support development of
new assays. It would also provide insights
into how an algorithm of incidence assays
could be assembled to provide better results.
Providing industry with access to the panels
for early feasibility testing and evaluation
would reduce one of the barriers to their
greater involvement. The Health Protection
Agency in the United Kingdom will now
establish such a repository and it is antici-
pated that a significant number of samples
will have been received by mid-2011 and
that data on the characteristics of existing
assays (and algorithms using them) will be
available in mid-2012. At this point, it is
hoped that there will be evidence of at least
one assay meeting the target product profile.
Next, the assays must undergo valida-
tion—that is, their incidence estimates
compared to other epidemiological infor-
mation such as measurements of incidence
from longitudinal cohorts. These validation
studies should ideally take place in a range
of communities (with different epidemic
phase,clade,antiretroviraltherapyuse,and
population type). This may be achieved in
partnershipwithexistingcohortstudiesthat
have archived specimens.
After validation, the normative guidelines
on incidence assays, reflecting which assays
have been fully evaluated and validated, will
be updated and publicised regularly. This
should include a standard method for
analysing data from incidence assays and
reporting results (including quantifying the
uncertainty in incidence estimates).
From 2013, the priority would shift to
supporting the scaled, quality-assured
manufacture of the assay. This support
may take the form of a purchase agree-
ment, for which the purchase of the tests is
guaranteed, reducing the risk for the
Box 2. Properties of an HIV Incidence Assay
Incidence Test Metrics
Incidence assays are used to estimate HIV incidence because they measure a well-
characterised biomarker for the recentness of infection. In the ideal case, the
assay works so that one result (‘‘test-positive’’) is returned for a period early in
infection and at other times a different result (‘‘test-negative’’) is returned. The
average time it takes for individuals to progress from the test-positive to the test-
negative state is called the mean duration, v (see Figure 2). Incidence can thus be
estimated as I~
NRz=NU
v
, where NRz is the number test-positive and NU is the
number not infected, and this formula is similar to the classic epidemiological
calculation, ‘‘Prevalence=Incidence6Duration’’ [22,23].
However, in practise, a subset of individuals in a population may not ever
progress to the test-negative stage, and some individuals that had progressed to
the test-negative state may later regress to the test-positive state. The proportion
of chronically infected individuals with a test positive result in a particular
population at a particular time can be measured (among a representative sample
of infected individuals known not to have been infected recently) and is termed
the false recent rate (FRR), e (see Figure 2). Note that this parameter is not
equivalent to the traditional definitions of test ‘‘specificity’’ or ‘‘negative
predictive value’’.
The updated statistical estimator that allows an unbiased estimate of HIV
incidence using an imperfect test (i.e., an FRR greater than zero) is
I~
NRz{
e
1{e

NR{
vNU
, where NR{ is the number of test-negative results [22].
But this estimator only works if the test characteristics (e and v) are accurately
and precisely measured for that particular population at that particular time (both
these parameters can vary substantially between populations and over time
[8,11,18,37]). If the estimate for these calibration parameters is not accurate, there
will be substantial bias in the estimate of incidence [12,13,19]; and if they are not
precisely estimated, then incidence estimates will be uncertain even if the cross-
sectional population survey is large. Critically, the mean duration and the FRR
operate as a pair of parameters that jointly specify the test characteristics, so in any
calculation, the way in which those parameters are evaluated must be the same.
For many applications of the first generation assays, these test characteristics
have not been measured accurately for the population in which the test is being
used, and this is the reason that published assay-derived estimates have been
inaccurate [24] (see Figure 2).
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feasibility and potential form of such
agreements have now begun between
manufacturers, donors, and funders.
In parallel, there should also be invest-
ment in the development of new biomark-
ers for improved assays in the medium to
long term, and NIH has issued a program
announcement (PA-10-212) for proposals
with this aim. Examples of new possibili-
ties for biomarkers include cytokine pro-
files and within-individual viral diversity
measures, although it is too early to tell if a
usable and reliable assay could be created
to measure them.
Conclusions
Progress in recent years towards the use
of a robust and well characterised inci-
dence assay has been challenged by several
factors but many of these can now be
overcome. A new generation of incidence
assays promises to be more accurate, but
the appropriate adoption and implemen-
tation of these new tests requires close
alignment of evaluation, validation, and
commercialisation activities. We believe
that if this is achieved, and the information
is meaningfully triangulated with other
epidemiological and programme imple-
mentation information [15,16], then the
effectiveness and efficiency of our response
to the HIV epidemic will be enhanced,
and this will be to the benefit of all those
that remain at risk of HIV infection.
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